\u200b\u200bLa note interminist\u00e9rielle n\u00b0 DGS\/PP5\/DSS\/1C\/2026\/135 du 1er octobre 2026 pr\u00e9cise les modalit\u00e9s actualis\u00e9es de continuit\u00e9 de traitement des patients trait\u00e9s par la sp\u00e9cialit\u00e9 pharmaceutique LUMYKRAS\u00ae 120 mg, comprim\u00e9 pellicul\u00e9 (sotorasib), \u00e0 la suite du non-renouvellement de son autorisation d\u2019acc\u00e8s pr\u00e9coce. LUMYKRAS\u00ae b\u00e9n\u00e9ficiait, jusqu\u2019au 24 octobre 2026, d\u2019une mise \u00e0 disposition \u00e0 titre gracieux par le laboratoire Amgen dans le cadre des continuit\u00e9s de traitement faisant suite \u00e0 la fin de l\u2019autorisation d\u2019acc\u00e8s pr\u00e9coce, conform\u00e9ment \u00e0 l\u2019article L. 162-16-5-4 du code de la s\u00e9curit\u00e9 sociale. La note organise la poursuite de ces traitements pour une p\u00e9riode suppl\u00e9mentaire de douze mois \u00e0 compter du 25 octobre 2026, pour les patients d\u00e9j\u00e0 trait\u00e9s.<\/p>\n
Le document est sign\u00e9 par la ministre de la sant\u00e9, des familles, de l\u2019autonomie et des personnes handicap\u00e9es et par le ministre de l\u2019action et des comptes publics. Il est adress\u00e9 aux directeurs g\u00e9n\u00e9raux des agences r\u00e9gionales de sant\u00e9 (ARS), avec copie aux coordinateurs des observatoires des m\u00e9dicaments, des dispositifs m\u00e9dicaux et de l\u2019innovation th\u00e9rapeutique (OMEDIT), ainsi qu\u2019aux directions g\u00e9n\u00e9rales de la Caisse nationale de l\u2019assurance maladie (CNAM) et de la Caisse centrale de la mutualit\u00e9 sociale agricole (CCMSA), qui sont directement concern\u00e9es par le suivi et le financement de ces continuit\u00e9s de traitement.<\/p>\n
La note rappelle le cadre juridique applicable, fond\u00e9 sur les articles L. 162-16-5-1 et L. 162-16-5-4 du code de la s\u00e9curit\u00e9 sociale, et s\u2019inscrit dans la continuit\u00e9 d\u2019une note d\u2019information interminist\u00e9rielle ant\u00e9rieure n\u00b0 DGS\/PP5\/DSS\/1C\/2025\/156 du 29 octobre 2025 relative aux modalit\u00e9s de continuit\u00e9 de traitement. Les dispositions pr\u00e9vues s\u2019appliquent \u00e9galement dans les d\u00e9partements et r\u00e9gions d\u2019outre-mer, ainsi qu\u2019\u00e0 Saint-Barth\u00e9lemy et Saint-Martin, assurant une homog\u00e9n\u00e9it\u00e9 territoriale de la prise en charge.<\/p>\n
Sur le plan des enjeux de politique de sant\u00e9, ce dispositif vise \u00e0 garantir la continuit\u00e9 th\u00e9rapeutique pour les patients d\u00e9j\u00e0 sous sotorasib malgr\u00e9 la fin de l\u2019acc\u00e8s pr\u00e9coce, en encadrant la p\u00e9riode transitoire et en clarifiant les responsabilit\u00e9s des acteurs institutionnels (ARS, OMEDIT, CNAM, CCMSA). La note pr\u00e9cise par ailleurs les points de contact op\u00e9rationnels au sein de la Direction g\u00e9n\u00e9rale de la sant\u00e9 (bureau PP5) et de la Direction de la s\u00e9curit\u00e9 sociale (bureau 1C) pour le suivi de la mise en \u0153uvre.\u00a0 (contenu r\u00e9sum\u00e9 en fran\u00e7ais par l’IA) Lire la Suite<\/a><\/p>","protected":false},"excerpt":{"rendered":" \u200b\u200bLa note interminist\u00e9rielle n\u00b0 DGS\/PP5\/DSS\/1C\/2026\/135 du 1er octobre 2026 pr\u00e9cise les modalit\u00e9s actualis\u00e9es de continuit\u00e9 de traitement des patients trait\u00e9s par la sp\u00e9cialit\u00e9 pharmaceutique LUMYKRAS\u00ae 120 mg, comprim\u00e9 pellicul\u00e9 (sotorasib), […]<\/p>\n","protected":false},"author":1,"featured_media":3914,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[2,37],"tags":[120],"class_list":["post-19817","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sante-publique-et-systeme-de-soins","category-textes-officiels-des-ministeres-sociaux","tag-bulletins-officiels-social-gouv-fr"],"_links":{"self":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/19817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19817"}],"version-history":[{"count":0,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/19817\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/media\/3914"}],"wp:attachment":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}